OncoMatch/Clinical Trials/Divarasib
Divarasib (GDC-6036) Clinical Trials
Divarasib (GDC-6036) is an oral, once-daily, covalent KRAS G12C inhibitor developed by Genentech/Roche with a selectivity and potency profile designed to improve on first-generation agents. In Phase 1 evaluation, single-agent divarasib in KRAS G12C–mutant NSCLC showed a confirmed response rate of approximately 53% and median progression-free survival of 13.8 months — among the strongest single-agent results in the class. The Krascendo-170 Lung Phase 2/3 study evaluates divarasib plus pembrolizumab and platinum-based chemotherapy in treatment-naive advanced NSCLC; additional trials study combination with anti-EGFR therapy in KRAS G12C–mutant colorectal cancer, and early-phase studies are evaluating divarasib in pancreatic cancer. Eligibility requires confirmed KRAS G12C mutation and typically specifies prior treatment history.
Check eligibility by cancer type
Recruiting Divarasib trials
Ranked by phase and US site count.
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Hoffmann-La Roche
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Hoffmann-La Roche
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
How OncoMatch helps you find Divarasib trials
AI reads the protocol
OncoMatch reads the eligibility criteria for every Divarasib trial and extracts structured requirements — biomarkers, stage, prior therapy — from protocol text.
Enter your results
Select your cancer type and mark your biomarker results. Your data never leaves your device. OncoMatch instantly filters to trials you may qualify for.
See your matches
Each trial shows which criteria you meet, which you don't, and which need more information. Bring the shortlist to your oncologist.